Joint Pain Injections Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Joint Pain Injections Market Trends and Insights

Increasing Osteoarthritis Incidence and Aging Population

Global osteoarthritis cases among people aged 15-64 exerting direct pressure on payers to finance minimally invasive interventions that keep working adults productive. Japan sits at the high end of prevalence with 12,610.12 cases per 100,000, an indicator of treatment demand across industrialized Asia. Post-menopausal women are driving incremental volume: nearly one-half are projected to develop osteoarthritis by 2045.^{[1]Mi-Jin Lee et al., “Clinical outcomes of single versus multiple HA injections,” BMC Musculoskeletal Disorders, biomedcentral.com} These dynamics create a long-duration runway for injection therapies that defer or avoid joint replacement and maintain labor participation.

Accelerated Uptake of Single-Dose Viscosupplementation (HA)

Single-injection HA protocols cut follow-up visits while matching the efficacy of multi-injection regimens, reducing system utilization and patient travel costs. Analysis of 150,000 Korean beneficiaries showed a 44% lower total knee arthroplasty risk after single doses versus untreated cohorts, bolstering payer confidence. Industrial response is robust; BD lifted prefillable-syringe output sevenfold to satisfy anticipated demand. The operational win for providers fewer appointments has accelerated formulary placement in the United States, Germany and Japan, setting a medium-term positive arc for the joint pain injections market.

Wider Payer Support for PRP and Regenerative Therapies

UnitedHealthcare has formalized CPT coding for leukocyte-poor PRP, signalling maturity in reimbursement policy.^{[2]UnitedHealthcare, “2025 Medicare Advantage Medical Policy Updates,” uhcprovider.com} Meta-analyses confirm PRP outperforms HA on pain reduction at 6- and 12-month checkpoints, giving actuaries defensible long-term savings arguments. Employers now spend an average USD 52 per member per month on musculoskeletal programs that include PRP coverage when productivity gains outweigh premiums. As evidence consolidates, PRP volumes are forecast to expand rapidly, reinforcing regenerative medicine’s role inside the joint pain injections market.

Proliferation of Pain-Centric Ambulatory Surgery Centers (ASCs)

Orthopedic outpatient procedures are set to grow 13% this decade, and ASCs have cost profiles that are 40-60% lower than hospital outpatient departments.^{[3]Vizient Inc., “Orthopedic Outpatient Procedures Outlook,” vizientinc.com} CMS now reimburses shoulder replacements in ASC settings, indirectly lifting injection volumes because pre- and post-surgical pain management remains in the same facility. Lower overhead lets ASCs price injections competitively, enticing employer-sponsored plans to steer patients toward these sites. Short-term CAGR support is therefore strong in North America and spreading to high-income Asian urban clusters.

High Patient Out-of-Pocket Costs in Uninsured Segments

Coverage denials for viscosupplementation based on contested clinical value have forced some US patients to absorb the full USD 1,100–USD 1,800 per injection episode. Cigna still classifies orthopedic stem-cell therapies as “not medically necessary,” creating uneven benefit structures that suppress uptake. Internationally, many emerging-market payers reimburse surgery but not biologic injections, limiting access despite clinical need. Until definitive cost-effectiveness data influence public insurance rule-making, out-of-pocket exposure will continue to curb uptake.

Variability in Reimbursement and Procedural Coding

The 2025 Medicare Physician Fee Schedule altered relative value units for large-joint injections, forcing providers to re-model profitability. Local Coverage Determinations have barred amniotic-derived products, stalling growth in a potentially high-margin segment. Outside the United States, disparate device-versus-drug definitions create coding ambiguity that can delay payment up to 180 days, pressuring cash-flow at smaller practices. Unless global coding systems converge, injection adoption will be uneven across borders.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Injection Type: HA Dominates, PRP Accelerates

The joint pain injections market size for hyaluronic acid stood equal to 47.68% of total revenue in 2025. Long-term safety, broad payer acceptance, and rising single-dose use keep HA entrenched across knee and ankle indications. PRP revenue is forecasted for a 8.72% CAGR, gaining traction as randomized studies corroborate superior WOMAC and VAS scores at 12 months. 

Combination products that merge HA with collagen tripeptides or linkers appeal to severe osteoarthritis patients and could widen choice. However, the Centers for Medicare & Medicaid Services’ 2024 non-coverage determination for placental biologics narrows near-term expansion pathways. Over the forecast window, proven efficacy endpoints and payer alignment suggest PRP will chip away at HA’s dominance without dislodging it entirely from first-line status in the joint pain injections market.

By Injection Cycle: Three-Cycle Protocols Gain Momentum

Single-cycle regimens represented 58.03% of market value in 2025 as physicians embraced the convenience of one-and-done dosing. Evidence now shows three PRP injections deliver statistically greater pain relief than a single dose, forming the rationale for a 12.12% CAGR through 2031 for this segment. 

Five-cycle programs remain confined to severe cases because the incremental benefit plateaus after the third dose; consequently, payer willingness to reimburse beyond three sessions is waning. Manufacturers are therefore redesigning packaging—multi-chamber kits for three cycles—to remove compounding errors and shorten prep time, a move that reinforces the growth of mid-range dosing frequencies within the joint pain injections market.

By Application: Hip and Small Joints Rise

The knee and ankle cluster accounted for 43.35% of 2025 revenue, underpinned by high prevalence and mature clinical guidelines. Hip injections are climbing at an 11.38% CAGR as AI-guided ultrasound improves access to a deep joint previously served primarily by surgery. 

Shoulder and elbow volumes benefit from athletes extending playing careers into middle age, prompting specialized centers to adopt PRP plus HA combinations. Meanwhile, spine-related injections face stricter utilization review after audits uncovered double-billing and documentation lapses, leading to slower growth. Overall, modality expansion into hip and small-joint anatomies will diversify revenue streams across the joint pain injections market.

By End User: ASCs Outpace Hospitals

Hospitals preserved a 39.92% share in 2025 due to integrated imaging and anesthesia resources. Yet ASCs are on course for a 12.98% CAGR, propelled by bundled-payment acceptance and patient preference for lower copays. Orthopedic clinics continue to serve as referral hubs, but regulatory oversight of high-volume pain centers is tightening and may redistribute volume toward accredited facilities with robust data reporting. 

Sports medicine centers capture elective demand among active seniors who value rapid recovery, while initial home-based pilot programs using portable ultrasound remain experimental. The overarching shift to value-based payment aligns with ASC strengths, signaling continued share gains at hospitals’ expense within the joint pain injections market.

Geography Analysis

North America delivered 36.28% of 2025 sales, anchored by the United States where Medicare Advantage now reimburses PRP under specified CPT codes and employer MSK programs average USD 52 per member per month. Canada’s single-payer model has begun funding HA in earlier disease stages, spurring 8% procedural growth. Mexico shows latent demand but still contends with uneven device registration timelines and out-of-pocket barriers, limiting near-term uptake.

Europe benefits from synchronized Medical Device Regulation that clarifies safety benchmarks for HA syringes. Germany and France drive regional procedure volume through robust outpatient networks, while the United Kingdom’s National Health Service pilots risk-share contracts tying reimbursement to functional-outcome thresholds. Southern European countries such as Spain and Italy are scaling AI-guided ultrasound to rural clinics, boosting accessibility.

Asia-Pacific is the fastest-growing territory at 10.79% CAGR, propelled by Japan’s exceptional osteoarthritis burden and well-established imaging infrastructure. China’s National Medical Products Administration has slashed device approval timelines to 150 days, accelerating market entry for single-dose HA brands. Australia, India and South Korea invest heavily in ASC construction, mirroring US practice patterns and unlocking procedural capacity. Rest-of-Asia markets exhibit early-adoption behavior with government-backed tele-ultrasound programs that may compress the diffusion curve for newer injection modalities.

Regulatory Landscape

Regulation for joint pain injections varies by modality and region, with hyaluronic acid (HA) intra-articular products in the United States historically regulated as higher-risk medical devices and requiring robust evidence packages for authorization and reimbursement. A recent anchor is Fidia Farmaceutici receiving US FDA Center for Devices and Radiological Health Premarket Approval (PMA) for HYMOVIS ONE (reported as April 2025) and then making it commercially available in the United States in January 2026, underscoring the continued importance of PMA pathways for differentiated viscosupplements.

In Europe, compliance requirements for HA injections are governed by the Medical Device Regulation (EU) 2017/745, which raises post-market clinical follow-up and real-world evidence expectations across legacy and new products. In parallel, the European Medicines Agency updated post-authorization expectations for centrally authorized products via revisions that became applicable in January 2026, including the revised variations framework and updated stability testing guidance for variations, increasing procedural and quality-system workload for manufacturers managing product changes across markets.

Market Opportunities and Future Outlook

A key whitespace is the push toward fewer-visit care pathways (single-injection and clinic-efficient protocols) that align with payer scrutiny and site-of-care shifts. Recent approvals and launches reinforce this direction: Fidia Farmaceutici brought HYMOVIS ONE, a single-injection, non-avian HA hydrogel, to the US market in January 2026 following FDA PMA, and this type of product profile supports providers and ASCs seeking to reduce follow-up visits while maintaining outcomes.

Another opportunity area sits around clinically validated regenerative and disease-modifying approaches that go beyond short-term symptom control, but face higher evidence thresholds and professional-society scrutiny. Pipeline movement provides tangible signals, including Biosplice Therapeutics submitting an NDA to the US FDA in January 2026 for lorecivivint for knee osteoarthritis, and MEDIPOST reporting in May 2026 that its Japan Phase 3 trial for CARTISTEM met primary and secondary endpoints. At the same time, the American Association of Hip and Knee Surgeons (AAHKS) released a 2025 biologics position statement cautioning against cartilage-restoration claims in hips and knees, which elevates the value of products supported by rigorous endpoints, registries, and defensible labeling for payers and employer MSK programs.